Natural Products as Pharmaceuticals and Sources for Lead Structures

The Practice of Medicinal Chemistry

Volumn , Issue , 2008, Pages 159-186

  Newman, David J ^a   Cragg, Gordon M ^a   Kingston, David G I ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882530319     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374194-3.00008-1     Document Type: Chapter

References (235)

1. Borchardt J.K. The beginnings of drug therapy: Ancient mesopotamian medicine. Drug News Perspect 2002, 15:187-192.
2. Huang K.C. The Pharmacology of Chinese Herbs 1999, CRC Press, Boca Raton, FL. 2nd Edition.
3. Kapoor L.D. CRC Handbook of Ayurvedic Medicinal Plants 1990, CRC Press, Boca Raton, FL.
4. Dev S. Ancient-modern concordance in ayurvedic plants: some examples. Environ. Health Persp. 1999, 107:783-789.
5. Johnson T. CRC Ethnobotany Desk Reference 1999, CRC Press, Boca Raton, FL.
6. Moerman D.E. Medicinal Plants of Native America 1986, Vol. 1. University of Michigan Museum of Anthropology, Ann Arbor, MI.
7. Farnsworth N.R., Akerele R.O., Bingel A.S., Soejarto D.D., Guo Z. Medicinal plants in therapy. Bull. World Health Org. 1985, 63:965-981.
8. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007, 70:461-477.
9. Class S. Pharma overview. Chem. Eng. News 2002, 80(48):39-49.
10. Rouhi M. Rediscovering natural products. Chem. Eng. News 2003, 81(41):77-91.
11. Borman S. Improving efficiency. Chem. Eng. News 2006, 84(25):56-78.
12. Borman S. Organic lab sparks drug discovery. Chem. Eng. News. 2002, 80(40):23-24.
13. Wilson R.M., Danishefsky S.J. Applications of total synthesis to problems in neurodegeneration: Fascinating chemistry along the weay. Acc. Chem. Res. 2006, 39:539-549.
14. Haslam E. Secondary metabolism - fact and fiction. Nat. Prod. Rep. 1986, 3:217-249.
15. Williams D.H., Stone M.J., Hauck P.R., Rahman S.K. Why are secondary metabolites (natural products) biosynthesized?. J. Nat. Prod. 1989, 52:1189-1208.
16. Harborne J.B. Role of secondary metabolites in chemical defence mechanisms in plants. Bioactive Compounds from Plants 1990, 126-139. John Wiley & Sons, Chichester. D.J. Chadwick, J. Marsh (Eds.).
17. Schröeder F.C., Farmer J.J., Attygalle A.B., Smedley S.R., Eisner T., Meinwald J. Combinatorial chemistry in insects: a library of defensive macrocyclic polyamines. Science 1998, 281:428-431.
18. Bulaj G., Buczek O., Goodsell I., Jiminez E.C., Kranski J., Nielsen J.S., Garrett J.E., Olivera B.M. Efficient oxidative folding of conotoxins and the radiation of venomous cone snails. Proc. Natl. Acad. Sci. USA 2003, 100:14562-14568.
19. Wallace M.S. Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain. Expert Rev. Neurother. 2006, 6:1423-1428.
20. Czaran T.L., Hoekstra R.F., Pagie L. Chemical warfare between microbes promotes biodiversity. Proc. Natl. Acad. Sci. USA 2002, 99:786-790.
21. Bais H.P., Vepachedu R., Gilroy S., Callaway R.M., Vivanco J.M. Allelopathy and exotic plant invasion: from molecules and genes to species interactions. Science 2003, 301:1377-1380.
22. Fitter A. Making allelopathy respectable. Science 2003, 301:1337-1338.
23. Everts S. Bacterial conversations. Chem. Eng. News 2006, 84(43):17-26.
24. Rice S.A., Mcdougald D., Kumar N., Kjelleberg S. The use of quorum-sensing blockers as therapeutic agents for the control of biofilm-associated infections. Curr. Opin. Investig. Drugs 2005, 6:178-184.
25. Geske G.D., Wezeman R.J., Siegel A.P., Blackwell H.E. Small molecule inhibitors of bacterial quorum sensing and biofilm formation. J. Am. Chem. Soc. 2005, 127:12762-12763.
26. Meijer L. Le cycle de division cellulaire et sa regulation. Oncologie 2003, 5:311-326.
27. Newman D.J., Cragg G.M., Snader K.M. The influence of natural products upon drug discovery. Nat. Prod. Rep. 2000, 17:215-234.
28. Wang J., Soisson S.M., Young K., Shoop W., Kodali S., Galgoci A., Painter R., Parthasarathy G., Tang Y.S., Cummings R., Ha S., Dorso K., Motyl M., Jayasuriya H., Ondeyka J., Herath K., Zhang C., Hernandez L., Allocco J., Basilio A., Tormo J.R., Genilloud O., Vicente F., Pelaez F., Colwell L., Lee S.H., Michael B., Felcetto T., Gill C., Silver L.L., Hermes J.D., Bartizal K., Barrett J., Schmatz D., Becker J.W., Cully D., Singh S.B. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 2006, 441:358-361.
29. Tremblay J.-F. Working the library. Singapore's Merlion builds a business out of its rich library of natural compounds. Chem. Eng. News 2006, 84(10):44.
30. Downes D., Laird S.A., Klein C., Carney B.K. Biodiversity prospecting contract. Biodiversity Prospecting: Using Genetic Resources for Sustainable Development 1993, 255-287. World Resources Institute, Washington, DC. W.V. Reid, S.A. Laird, C.A. Meyer, R. Gamez, A. Sittenfeld, D.H. Janzen, M.A. Gollin, C. Juma (Eds.).
31. ten Kate, K., Wells, A. Benefit-sharing case study. The access and benefit-sharing policies of the United States National Cancer Institute: a comparative account of the discovery and development of the drugs calanolide and topotecan. Submission to the Executive Secretary of the Convention on Biological Diversity. The Royal Botanic Gardens: Kew, UK, 1998.
32. ten Kate K., Laird S.A. The commercial use of biodiversity. Access to genetic resources and benefit-sharing 1999, Earthscan Publications Ltd., London, UK.
33. Rosenthal J.P. Drug discovery, economic development and conservation: the international cooperative biodiversity groups. Pharm. Biol. 1999, 37:5.
34. Balick M.J. Ethnobotany and the identification of therapeutic agents from the rainforest. Bioactive Compounds from Plants 1990, 22-39. John Wiley & Sons, Chichester. D.J. Chadwick, J. Marsh (Eds.).
35. Cox P.A. Ethnopharmacology and the search for new drugs. Bioactive Compounds from Plants 1990, 40-55. John Wiley & Sons, Chichester. D.J. Chadwick, J. Marsh (Eds.).
36. Farnsworth N.R. The role of ethnopharmacology in drug development. Bioactive Compounds from Plants 1990, 2-21. John Wiley & Sons, Chichester. D.J. Chadwick, J. Marsh (Eds.).
37. Plotkin M.J. Conservation, ethnobotany and the search for new jungle medicines: pharmacognosy comes of age again. Pharmacotherapy 1988, 8:257-262.
38. Balandrin M.F., Kinghorn A.D., Farnsworth N.R. Human Medicinal Agents from Plants 1993, Vol. 534:2-12. American Chemical Society, Washington, DC. A.D. Kinghorn, M.F. Balandrin (Eds.).
39. Raskin I., Ribnicky D.M., Komarnytsky S., Ilic N., Poulev A., Borisjuk N., Brinker A., Moreno D.A., Ripoll C., Yakoby N., O'Neal J.M., Cornwell T., Pastor I., Fridlander B. Plants and human health in the twenty-first century. Trends Biotechnol. 2002, 20:522-531.
40. Newman D.J., Cragg G.M. Marine natural products and related compounds in clinical and advanced preclinical trials. J. Nat. Prod. 2004, 67:1216-1238.
41. Newman D.J., Hill R.T. New drugs from marine microbes: the tide is turning. J. Ind. Microbiol. Biotechnol. 2006, 33:539-544.
42. Diyabalanage T., Amsler C.D., McClintock J.B., Baker B.J. Palmerolide A, a cytotoxic macrolide from the antarctic tunicate Synoicum adareanum. J. Am. Chem. Soc. 2006, 128:5630-5631.
43. Nicolaou K.C., Ramakrishna G., Sun Y.-P., Banerji B., Chen D.Y.K. Synthesis of the originally proposed and revised structures of palmerolide A. Angew. Chem. Int. Ed. 2007, 46:5896-5900.
44. Perry N.B., Ettouati L., Litaudon M., Blunt J.W., Munro M.H.G. Alkaloids from the antarctic sponge Kirkpatrickia varialosa. Part 1: variolin B, a new antitumour and antiviral compound. Tetrahedron 1994, 50:3987-3992.
45. Trimurtulu G., Faulkner D.J., Perry N.B., Ettouati L., Litaudon M., Blunt J.W., Munro M.H.G., Jameson G.B. Alkaloids from the antarctic sponge Kirkpatrickia varialosa. Part 2: variolin A and N(3')-methyl tetrahydrovariolin B. Tetrahedron 1994, 50:3993-4000.
46. Ahaidar A., Fernández D., Danelón G., Cuevas C., Manzanares I., Albericio F., Joule J.A., Álvarez M. Total syntheses of variolin B and deoxyvariolin B1. J. Org. Chem. 2003, 68:10020-10029.
47. Poulev A., O'Neal J.M., Logendra S., Pouleva R.B., Timeva V., Garvey A.S., Gleba D., Jenkins I.S., Halpern B.T., Kneer R., Cragg G.M., Raskin I. Elicitation, a new window into plant chemodiversity and phytochemical drug discovery. J. Med. Chem. 2003, 2542-2547.
48. McCoy E., O'Connor S.E. Directed biosynthesis of alkaloid analogs in the medicinal plant. Catharanthus roseus. J. Am. Chem. Soc. 2006, 128:14276-14277.
49. Pace N.R. A molecular view of microbial diversity and the biosphere. Science 1997, 276:734-740.
50. Madigan M.T., Martinko J.M., Parker J.B. Biology of Micro-organisms 1996, Prentice-Hall, Upper Saddle River, NJ. 8th Edition.
51. McAlpine J.B., Bachmann B.O., Piraee M., Tremblay S., Alarco A.-M., Zazopoulos E., Farnet C.M. Microbial genomics as a guide to drug discovery and structural elucidation: ECO-02301, a novel antifungal agent, as an example. J. Nat. Prod. 2005, 68:493-496.
52. Lautru S., Deeth R.J., Bailey L., Challis G.M. Discovery of a new peptide natural product by Streptomyces coelicolor genome mining. Nat. Chem. Biol. 2005, 1:265-269.
53. Zengler K., Toledo G., Rappe M., Elkins J., Mathur E.J., Short J.M., Keller M. Cultivating the uncultured. Proc. Nat. Acad. Sci. USA 2002, 99:15681-15686.
54. Udwary D.W., Zeigler L., Asolkar R.N., Singan V., Lapidus A., Fenical W., Jensen P.R., Moore B.S. Genome sequencing reveals comples secondary metabolome in the marine actinomycete Salinispora tropica. Proc. Natl. Acad. Sci. USA 2007, 104:10376-10381.
55. Gontang E.A., Fenical W., Jensen P.R. Phylogenetic Diversity of Gram-positive bacteria cultured from marine sediments. Appl. Environ. Microbiol. 2007, 73:3272-3282.
56. Abe F., Horikoshi K. The biotechnological potential of piezophiles. Trends Biotechnol. 2001, 19:102-108.
57. Amato A. Microbes live near undersea CO2 lake. Chem. Eng. News 2006, 84(38):14.
58. Persidis A. Extremophiles. Nat. Biotechnol. 1998, 16:593-594.
59. Rossi M., Ciaramella M., Cannio R., Pisani F.M., Moracci M., Bartolucci S. Extremophiles 2002. J. Bacteriol. 2003, 185:3683-3689.
60. Short P.L. New Zealand plays to its strengths. Chem. Eng. News 2007, 85(4):20-21.
61. Cavicchioli R., Siddiqui K.S., Andrews D., Sowers K.R. Low-temperature extremophiles and their applications. Curr. Opin. Biotechnol. 2002, 13:253-261.
62. Gomes J., Steiner W. Food Technol. Biotechnol. 2004, 42.
63. Hoyoux A., Blaise V., Collins T., D'Amico S., Gratia E., Huston A.L., Marx J.C., Sonan G., Zeng Y.X., Feller G., Gerday C. Extreme catalysts from low-temperature environments. J. Biosci. Bioeng. 2004, 98:317-330.
64. Schiraldi C., De Rosa M. The production of biocatalysts and biomolecules from extremophiles. Trends Biotechnol. 2002, 20:515-521.
65. van den Burg B. Extremophiles as a source for novel enzymes. Curr. Opin. Microbiol. 2003, 6:213-218.
66. Wiegel J., Kevbrin V.V. Alkalithermophiles. Biochem. Soc. Trans. 2004, 32:193-198.
67. Johnson D.B., Hallberg K.B. The microbiology of acidic mine waters. Res. Microbiol. 2003, 154:466-473.
68. Stierle A.A., Stierle D.B., Kemp K. Novel sesquiterpenoid matrix metalloproteinase-3 inhibitors from an acid mine waste extremophile. J. Nat. Prod. 2004, 67:1392-1395.
69. Stierle D.B., Stierle A.A., Hobbs D., Stokken J., Clardy J. Berkeleydione and berkeleytrione, new bioactive metabolites from an acid mine organism. Org. Lett. 2004, 6:1049-1052.
70. Gunatilaka A.A.L. Natural products from plant-associated micro-organisms: distribution, structural diversity, bioactivity, and implications of their occurrence. J. Nat. Prod. 2006, 69:509-526.
71. Strobel G., Daisy B., Castillo U., Harper J. Natural products from endophytic microorganisms. J. Nat. Prod. 2004, 67:257-268.
72. Tan R.X., Zou W.X. Endophytes: a rich source of functional metabolites. Nat. Prod. Rep. 2001, 18:448-459.
73. Castillo U., Harper J.K., Strobel G.A., Sears J., Alesi K., Ford E., Lin J., Hunter M., Maranta M., Ge H., Yaver D., Jensen J.B., Porter H., Robinson R., Millar D., Hess W.M., Condron M., Teplow D. Kakadumycins, novel antibiotics from Streptomyces sp. NRRL 30566, an endophyte of Grevillea pteridifolia. FEMS Microbiol. Lett. 2003, 224:183-190.
74. Li J.Y., Harper J.K., Grant D.M., Tombe B.O., Bashyal B., Hess W.M., Strobel G.A. Ambuic acid, a highly functionalized cyclohexenone with antifungal activity from Pestalotiopsis spp. and Monochaetia sp. Phytochemistry 2001, 56:463-468.
75. Ezra D., Castillo U.F., Strobel G.A., Hess W.M., Porter H., Jensen J.B., Condron M.A., Teplow D.B., Sears J., Maranta M., Hunter M., Weber B., Yaver D. Coronamycins, peptide antibiotics produced by a verticillate Streptomyces sp. (MSU-2110) endophytic on Monstera sp. Microbiology 2004, 150:785-793.
76. Zhou G.-K., Wijeratne E.M.K., Bigelow D., Pierson L.S., VanEtten H.D., Gunatilaka A.A.L. Aspochalasins, I, J, and K: three new cytotoxic cytochalasans of Aspergillus flavipes from the rhizosphere of Ericameria laricifolia of the Sonoran desert. J. Nat. Prod. 2004, 67:328-332.
77. Bok J.W., Hoffmeister D., Maggio-Hall L.A., Murillo R., Glasner J.D., Keller N.P. Genomic mining for Aspergillus natural products. Chem. Biol. 2006, 13:31-37.
78. Hoffmeister D., Keller N.P. Natural products of filamentous fungi: enzymes, genes, and their regulation. Nat. Prod. Rep. 2007, 24:393-416.
79. Stierle A., Strobel G., Stierle D. Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew. Science 1993, 260:214-216.
80. Li J.-Y., Sidhu R.S., Bollon A., Strobel G.A. Stimulation of taxol production in liquid cultures of Pestalotiopsis microspora. Mycolog. Res. 1998, 102:461-464.
81. Puri S.C., Verma V., Amna T., Qazi G.N., Spiteller M. An endophytic fungus from Nothapodytes foetida that produces camptothecin. J. Nat. Prod. 2005, 68:1717-1719.
82. Amna T., Puri S.C., Verma V., Sharma J.P., Khajuria R.K., Musarrat J., Spiteller M., Qazi G.N. Bioreactor studies on the endophytic fungus Entrophosphora infrequens for the production of an anticancer alkaloid camptothecin. Can. J. Microbiol. 2006, 52:189-196.
83. Eyberger A.L., Dondapati R., Porter J.R. Endophyte fungal isolates from Podophyllum peltatum produce podophyllotoxin. J. Nat. Prod. 2006, 69:1121-1124.
84. Puri S.C., Nazir A., Chawla R., Arora R., Riyaz-ul-Hasan S., Amna T., Ahmed B., Verma V., Singh S., Sagar R., Sharma A., Kumar R., Sharma R.K., Qazi G.N. The endophytic fungus Trametes hirsuta as a novel alternative source of podophyllotoxin and related tetralin lignans. J. Biotech. 2006, 122:494-510.
85. Guo B., Li H., Zhang L. Isolation of a fungus producing vinblastine. J. Yunnan Univ. 1998, 20:214-215.
86. Zhang L.Q., Guo B., Li H., Zeng S., Shao H., Gu S., Wei R. Preliminary study on the isolation of endophytic fungus of Catharanthus roseus and its fermentation to produce products of therapeutic value. Zhong Cao Yao (Chinese Tradit. Herb. Drugs) 2000, 31:805-807.
87. Yang X., Zhang L., Guo B., Guo S. Preliminary study of a vincristine-producing endophytic fungus isolated from leaves of Catharanthus roseus. Zhong Cao Yao (Chinese Tradit. Herb. Drugs) 2004, 35:79-81.
88. Rouhi A.M. Deep-sea harvest. Chem. Eng. News 2006, 84(15):67-70.
89. Mincer T.J., Jensen P.R., Kauffman C.A., Fenical W. Widespread and persistent populations of a major new marine Actinomycete taxon in ocean sediments. Appl. Environ. Microbiol. 2002, 68:5005-5011.
90. Feling R.H., Buchanan G.O., Mincer T.J., Kauffman C.A., Jensen P.R., Fenical W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew. Chem. Int. Ed. 2003, 42:355-357.
91. Kwon H.C., Kauffman C.A., Jensen P.R., Fenical W. Marinomycins A-D, antitumor-antibiotics of a new structure class from a marine actinomycete of the recently discovered genus "Marinispora". J. Am. Chem. Soc. 2006, 128:1622-1632.
92. Piel J. Metabolites from symbiotic bacteria. Nat. Prod. Rep. 2004, 21:519-538.
93. Yu T.-W., Floss H.G. Ansamitocins (maytansinoids). Anticancer Agents from Natural Products 2005, 321-337. Taylor and Francis, Boca Raton, FL. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
94. Piel J., Butzke D., Fusetani N., Hui D., Platzer M., Wen G., Matsunaga S. Exploring the chemistry of uncultivated bacterial symbionts: antitumor polyketides of the pederin family. J. Nat. Prod. 2005, 68:472-479.
95. Piel J., Hofer I., Hui D. Evidence for a symbiosis island involved in horizontal acquisition of pederin biosynthetic capabilities by the bacterial symbiont of Paederus fuscipes beetles. J. Bacteriol. 2004, 186:1280-1286.
96. Piel J., Hui D., Wen G., Butzke D., Platzer M., Fusetani N., Matsunaga S. Antitumor polyketide biosynthesis by an uncultivated bacterial symbiont of the marine sponge Theonella swinhoei. Proc. Nat. Acad. Sci. USA 2004, 101:16222-16227.
97. Partida-Martinez L.P., Hertweck C. Pathogenic fungus harbours endosymbiotic bacteria for toxin production. Nature 2005, 437:884-888.
98. Khosla C. Natural product biosynthesis: a new interface between enzymology and medicine. J. Org. Chem. 2000, 65:8127-8133.
99. Staunton J., Weissman K.J. Polyketide biosynthesis: a millennium review. Nat. Prod. Rep. 2001, 18:380-416.
100. Walsh C.T. Polyketide and nonribosomal peptide antibiotics: modularity and versatility. Science 2004, 16:1805-1810.
101. Walsh C.T. The chemical versatility of natural-product assembly lines. Acc. Chem. Res. 2007, 40. DOI: 10.1021/ar7000414.
102. Clardy J., Walsh C.T. Lessons from natural molecules. Nature 2004, 432:829-837.
103. Thomas M.G., Bixby K.A., Shen B. Combinatorial biosynthesis of anticancer natural molecules. Anticancer Agents from Natural Products 2005, 519-552. Taylor and Francis, Boca Raton, FL. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
104. Julien B., Shah S., Ziemann R., Goldman R., Katz L., Khosla C. Isolation and characterization of the epothilone biosynthetic gene cluster from Sorangium cellulosum. Gene 2000, 249:153-160.
105. Molnar I., Schupp T., Ono M., Zirkle R.E., Milnamow M., Nowak-Thompson B., Engel N., Toupet C., Stratmann A., Cyr D.D., Gorlach J., Mayo J.M., Hu A., Goff S., Schmid J., Ligon J.M. The biosynthetic gene cluster for the microtubule-stabilizing agents epothilones A and B from Sorangium cellulosum So ce90. Chem. Biol. 2000, 7:97-109.
106. Lau J., Frykman S., Regentin R., Ou S., Tsuruta H., Licari P. Optimizing the heterologous production of epothilone D in Myxococcus xanthus. Biotechnol. Bioeng. 2002, 78:280-288.
107. Beutler J.A., McKee T.C., Fuller R.W., Tischler M., Cardellina J.H., McCloud T.G., Snader K.M., Boyd M.R. Frequent occurrence of HIV-inhibitory sulfated polysaccharides in marine invertebrates. Antiviral Chem. Chemother. 1993, 3:167-172.
108. Cardellina J.H., Munro M.H.G., Fuller R.W., Manfredi K.P., McKee T.C., Tischler M., Bokesch H.R., Gustafson K.R., Beutler J.A., Boyd M.R. A chemical-screening strategy for the dereplication and prioritization of HIV-inhibitory aqueous natural-products extracts. J. Nat. Prod. 1993, 56:1123-1129.
109. Coombes J.D. New Drugs from Natural Sources 1992, IBC Technical Services, London.
110. Boyd M.R., Paull K.D. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev. Res. 1995, 34:91-109.
111. Johnson R.K., Bartus H.F., Hofmann G.A., Bartus J.O., Mong S.-M., Faucette L.F., McCabe F.L., Chan J.A., Mirabelli C.K. Discovery of new DNA-reactive drugs. In Vitro and In Vivo Models for Detection of New Antitumor Drugs 1986, 15-26. University of Tokyo Press, Tokyo. L.J. Hanka, T. Kondo, R.J. White (Eds.).
112. Meyer B.N., Ferrigni N.R., Putnam J.E., Jacobsen L.B., Nichols D.E., McLaughlin J.L. Brine shrimp: a convenient general bioassay for active plant constituents. Planta Med. 1982, 45:31-34.
113. McLaughlin J.L. Crown gall tumours on potato discs and brine shrimp lethality: two simple bioassays for higher plant screening and fractionation. Methods in Plant Biochemistry: Assays for Bioactivity 1991, Vol. 6:1-32. Academic Press, San Diego, CA. K. Hostettmann (Ed.).
114. Klekota J., Brauner E., Roth F.P., Schreiber S.L. Using high-throughput screening data to discriminate compounds with single-target effects from those with side effects. J. Chem. Inf. Model 2006, 46:1549-1562.
115. Liu B., Li S., Hu J. Technological advances in high-throughput screening. Am. J. Pharmacogen. 2004, 4:263-276.
116. Mullin R. Drug discovery. Chem. Eng. News 2004, 82(30):23-32.
117. Shimizu Y. Bioactive marine natural products with emphasis on handling of water-soluble compounds. J. Nat. Prod. 1985, 48:223-235.
118. Marston A., Hostettmann K. Modern separation methods. Nat. Prod. Rep. 1991, 8:391-413.
119. Gronquist M., Meinwald J., Eisner T., Schroeder F.C. Exploring uncharted terrain in nature's structure space using capillary NMR spectroscopy: 13 steroids from 50 fireflies. J. Am. Chem. Soc. 2005, 127:10810-10811.
120. Hostettmann K., Wolfender J.-L., Rodriguez S. Rapid detection and subsequent isolation of bioactive constituents of crude plant extracts. Planta Med. 1997, 63:2-10.
121. Jaki B., Franzblau S., Pauli G.F. An NMR method towards the routine chiral determination of natural products. Phytochem. Anal. 2004, 15:213-219.
122. Konishi Y., Kiyota T., Draghici C., Gao J.M., Yeboah F., Acoca S., Jarussophon S., Purisima E. Molecular formula analysis by an MS/MS/MS technique to expedite dereplication of natural products. Anal. Chem. 2007, 79:1187-1197.
123. Lambert M., Wolfender J.L., Staerk D., Christensen B., Hostettmann K., Jaroszewski J.W. Identification of natural products using HPLC-SPE combined with CapNMR. Anal. Chem. 2007, 79:727-735.
124. Wolfender J.L., Queiroz E.F., Hostettmann K. Phytochemistry in the microgram domain - a LC-NMR perspective. Mag. Res. Chem. 2005, 43:697-709.
125. Cordell G.A. Changing strategies in natural products chemistry. Phytochemistry 1995, 40:1585-1612.
126. Friesen J.B., Pauli G.F. G.U.E.S.S. - a generally useful estimate of solvent systems for CCC. J. Liq. Chromatogr. Rel. Technol. 2005, 28:2777-2806.
127. Pauli G.F., Jaki B.U., Lankin D.C. Quantitative 1H NMR: development and potential of a method for natural product analysis. J. Nat. Prod. 2005, 68:138-149.
128. Cragg G.M., Schepartz S.A., Suffness M., Grever M.R. The taxol supply crisis. New NCI policies for handling the large-scale production of novel natural product anticancer and anti-HIV agents. J. Nat. Prod. 1993, 56:1657-1668.
129. Fujita Y. Industrial production of shikonin and berberine. Applications of Plant Cell and Tissue Culture 1988, 157-174. John Wiley & Sons, Chichester. G. Bock, J. Marsh (Eds.).
130. Fowler M.W., Cresswell R.C., Stafford A.M. An economic and technical assessment of the use of plant cell cultures for natural product synthesis on an industrial scale. Bioactive Compounds from Plants 1990, 228-238. John Wiley & Sons, Chichester. D.J. Chadwick, J. Marsh (Eds.).
131. Kingston D.G.I. Taxol and its analogs. Anticancer Agents from Natural Products 2005, 89-122. CRC Press, Boca Raton, FL. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
132. 7-24 and finale. Org. Process Res. Dev. 2004, 8:122-130.
133. Yu M.J., Kishi Y., Littlefield B.A. Discover of E7389, a fully synthetic macrocyclic ketone analog of halichondrin B. Anticancer Agents from Natural Products 2005, 241-265. Taylor and Francis, Boca Raton, FL. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
134. Burke M.D., Berger E.M., Schreiber S.L. Generating diverse skeletons of small molecules combinatorially. Science 2003, 302:613-618.
135. Burke M.D., Schreiber S.L. A planning strategy for diversity-oriented synthesis. Angew. Chem. Int. Ed. 2004, 43:46-58.
136. Borman S. The many faces of combinatorial chemistry. Chem. Eng. News 2003, 81(43):45-56.
137. Borman S. Rescuing combichem. Diversity-oriented synthesis (DOS) aims to pick up where traditional combinatorial chemistry left off. Chem. Eng. News 2004, 82(40):32-40.
138. Nicolaou K.C., Roschangar F., Vourloumis D. Chemical biology of epothilones. Angew. Chem. Int. Ed. 1998, 37:2014-2045.
139. Evans B.E., Rittle K.E., Bock M.G., DiPardo R.M., Fredinger R.M., Whitter W.L., Lundell G.F., Veber D.F., Anderson P.S., Chang R.S.L., Lotti V.J., Cerino D.J., Chen T.B., Kling P., Kunkel K.A., Springer J.P., Hirshfield J. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 1988, 16:2235-2246.
140. Nicolaou K.C., Pfefferkorn J.A., Roecker A.J., Cao G.Q., Barluenga S., Mitchell H.J. Natural product-like combinatorial libraries based on privileged structures. 1. General principles and solid-phase synthesis of benzopyrans. J. Am. Chem. Soc. 2000, 122:9939-9953.
141. Nicolaou K.C., Pfefferkorn J.A., Barluenga S., Mitchell H.J., Roecker A.J., Cao G.-O. Natural product-like combinatorial libraries based on privileged structures. 3. The "libraries from libraries" principle for diversity enhancement of benzopyran libraries. J. Am. Chem. Soc. 2000, 122:9968-9976.
142. Nicolaou K.C., Pfefferkorn J.A., Mitchell H.J., Roecker A.J., Barluenga S., Cao G.O., Affleck R.L., Lillig J.E. Natural product-like combinatorial libraries based on privileged structures. 2. Construction of a 10,000-membered benzopyran library by directed split-and-pool chemistry using nanokans and optical encoding. J. Am. Chem. Soc. 2000, 122:9954-9967.
143. Breinbauer R., Vetter I.R., Waldmann H. From protein domains to drug candidates - natural products as guiding principles in the design and synthesis of compound libraries. Angew. Chem. Int. Ed. 2001, 41:2878-2890.
144. Koch M.A., Waldmann H. Protein structure similarity clustering and natural product structure as guiding principles in drug discovery. Drug Discov. Today 2005, 10:471-483.
145. Ferreira S.H. A bradykinin-potentiating factor present in the venom of Bothrops jararaca. Br. J. Pharmacol. 1965, 24:163-169.
146. Cushman D.W., Cheung H.S., Sabo E.F., Ondetti M.A. Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 1977, 5484-5491.
147. Ondetti M.A., Rubin B., Cushman D.W. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active hypertensive agents. Science 1977, 196:441-444.
148. Turk B. Targeting proteases: successes, failures and future prospects. Nat. Revs. Drug Discov. 2006, 5:785-799.
149. Endo A., Kuroda M., Tsujita Y., Terahara A., Tamura C. Physiologically active compounds. Ger. Pat. 2524355 1975.
150. Endo A. Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase. J. Med. Chem. 1985, 28:401-405.
151. Brown A.G., Smale T.C., King T.J., Hasenkamp R., Thompson R.H. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. J. Chem. Soc. Perkin Trans. 1 1976, 1:1165-1170.
152. Endo A., Monacolin K. A new hypocholesterolemic agent produced by a Monascus species. J. Antibiot. 1979, 32:852-854.
153. Endo A., Monacolin K. A new hypocholesterolemic agent that specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme a reductase. J. Antibiot. 1980, 33:334-336.
154. Alberts A.W., Chen J., Kuron G., Hunt V., Huff J., Hoffman C., Rothrock J., Lopez M., Joshua H., Harris E., Patchett A., Monaghan R., Currie S., Stapley E., Albers-Shonberg G., Hensens O., Hirshfield J., Hoogsteen K., Liesch J., Springer J. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol lowering agent. Proc. Natl. Acad. Sci. USA 1980, 77:3957-3961.
155. Monaghan, R. L., Alberts, A. W., Hoffman, C. G., Albers-Schonberg, G. Hypocholesteremic fermentation products and process of preparation. USP 4231938, 1980.
156. Alberts A.W., MacDonald J.S., Till A.E., Tobert J.A. Lovastatin. Cardiol. Drug Dev. 1989, 7:89-109.
157. Vagelos P.R. Are prescription drug prices high?. Science 1991, 252:1080-1084.
158. Rosenblum S.B., Huynh T., Afonso A., Davis H.R., Yumibe N., Clader J.W., Burnett D.A. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4- hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J. Med. Chem. 1998, 41:973-980.
159. Garcia-Calvo M., Lisnock J.-M., Bull H.G., Hawes B.E., Burnett D.A., Braun M.P., Crona J.H., Davis H.R., Dean D.C., Detmers P.A., Graziano M.P., Hughes M., MacIntyre D.E., Ogawa A., O'Neill K.A., Iyer S.P.N., Shevell D.E., Smith M.M., Tang Y.S., Makarewicz A.M., Ujjainwalla F., Altmann S.W., Chapman K.T., Thornberry N.A. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. USA 2005, 102:8132-8137.
160. Burnett J.R., Huff M.W. Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolemia. Expert Opin. Investig. Drugs 2006, 15:1337-1351.
161. Tsang C.K., Qi H., Liu L.F., Zheng X.F.S. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov. Today 2007, 27:112-124.
162. Koehn F.E. Therapeutic potential of natural product signal transduction agents. Curr. Opin. Biotech. 2006, 17:631-637.
163. Janin Y.L. Antituberculosis drugs: ten years of research. Bioorg. Med. Chem. 2007, 15:2479-2513.
164. Wright G.D., Sutherland A.D. New strategies for combating multidrug-resistant bacteria. Trends Mol. Med. 2007, 13:260-267.
165. Lam K.S. New aspects of natural products in drug discovery. Trends Microbiol. 2007, 15:279-289.
166. von Nussbaum F., Brands M., Hinzen B., Weigand S., Habich D. Antibacterial natural products in medicinal chemistry - exodus or revival?. Angew. Chem. Int. Ed. 2006, 45:5072-5129.
167. Cropp T.A., Wilson D.J., Reynolds K.A. Identification of a cyclohexylcarbonyl CoA biosynthetic gene cluster and application in the production of doramectin. Nat. Biotechnol. 2000, 18:980-983.
168. Hofle G., Reichenbach H. Epothilone, a myxobacterial metabolite with promising antitumor activity. Anticancer Agents from Natural Products 2005, 413-450. Taylor and Francis, Boca Raton, FL. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
169. Wilson R.M., Danishefsky S.J. Small molecule natural products in the discovery of therapeutic agents: the synthesis connection. J. Org. Chem. 2006, 1:8329-8351.
170. Altmann K.-H., Gertsch J. Anticancer drugs from nature-natural products as a unique source of new microtubule-stabilizing agents. Nat. Prod. Rep. 2007, 24:327-357.
171. Altmann K.-H., Pfeifer B., Arseniyadis S., Pratt B.A., Nicolaou K.C. The chemistry and biology of epothilones - the wheel keeps turning. ChemMedChem 2007, 2:396-423.
172. Pivot, X., Villanueva, C., Chaigneau, L., Nguyen, T., Demarchi, M., Maurina, T., Stein, U., Borg, C.Ixabepilone, a novel epothilone analog in the treatment of breast cancer Ixabepilone NDA granted priority review. Expert Opin. Invest. Drugs 2008, 17, 593-599.
173. Klar U., Buchmann B., Schwede W., Skuballa W., Hoffman J., Lichtner R.B. Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew. Chem. Int. Ed. 2006, 45.
174. Feyen F., Gertsch J., Wartmann M., Altmann K.-H. Design and synthesis of 12-aza-epothilones (azathilones) - "non-natural" natural products with potent anticancer activity. Angew. Chem. Int. Ed. 2006, 45:5880-5885.
175. Tse M.L., Watts R.E., Khosla C. Substrate tolerance of module 6 of the epothilone synthase. Biochemistry 2007, 46:3385-3393.
176. Arcamone F.M. Anthracyclines. Anticancer Agents from Natural Products 2005, 299-320. Taylor and Francis, Boca Raton, FL. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
177. Hecht S.M. Bleomycin group antitumor agents. Anticancer Agents from Natural Products 2005, 357-381. Taylor and Francis, Boca Raton, FL. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
178. Remers W.A. The mitomycins. Anticancer Agents from Natural Products 2005, 475-497. Taylor and Francis, Boca Raton, FL. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
179. Hamann P.R., Upeslacis J., Borders D.B. Enediynes. Anticancer Agents from Natural Products 2005, 451-474. Taylor and Francis, Boca Raton, FL. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
180. Prudhomme M. Staurosporines and structurally related indolocarbazoles as antitumor agents. Anticancer Agents from Natural Products 2005, 499-517. Taylor and Francis, Boca Raton, FL. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
181. Wani M.C., Taylor H.L., Wall M.E., Coggon P., McPhail A.T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 1971, 93:2325-2327.
182. Schiff P.B., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277:665-667.
183. Wang X., Itokawa H., Lee K.-H. Structure-activity relationships of taxoids. Taxus: The Genus Taxus 2003, 298-386. Taylor and Francis, London. H. Itokawa, K.-H. Lee (Eds.).
184. Cragg G.M., Newman D.J. A tale of two tumor targets: topoisomerase I and tubulin. The wall and wani contribution to cancer chemotherapy. J. Nat. Prod. 2004, 67:232-244.
185. Dubois J. Recent progress in the development of docetaxel and paclitaxel analogues. Expert Opin. Ther. Patents. 2006, 16:1481-1496.
186. Kingston D.G.I., Newman D.J. Taxoids: cancer-fighting compounds from nature. Curr. Opin. Drug Discov. Dev. 2007, 10:130-144.
187. Geney R., Chen J., Ojima I. Recent advances in the new generation taxane anticancer agents. Med. Chem. 2005, 1:125-139.
188. Kingston D.G.I., Jagtap P.G., Yuan H., Samala L. The chemistry of taxol and related taxoids. Progress in the Chemistry of Organic Natural Products 2002, Vol. 84:53-225. Springer, Wien. W. Herz, H. Falk, G.W. Kirby (Eds.).
189. Guenard D., Gueritte-Voegelein F., Potier P. Taxol and taxotere: discovery, chemistry, and structure-activity relationships. Acc. Chem. Res. 1993, 26:160-167.
190. Green M.R., Manikhas G.M., Orlov S., Afanasyev B., Makhson A.M., Bhar P., Hawkins M.J. Abraxane, a novel cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. 2006, 17:1263-1268.
191. Lee K.-H., Xiao Z. Podophyllotoxin and analogs. Anticancer Agents from Natural Products 2005, 71-87. CRC Press, Boca Raton, FL. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
192. Gueritte F., Fahy J. The vinca alkaloids. Anticancer Agents from Natural Products 2005, 123-135. CRC Press, Boca Raton, FL. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
193. Rahier N.J., Thomas C.J., Hecht S.M. Camptothecin and its analogs. Anticancer Agents from Natural Products 2005, 5-21. CRC Press, Boca Raton, FL. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
194. Anonymous Yondelis recommended for E.U. approval in soft tissue sarcoma. DailyDrugNews.com (Daily Essentials) 2007, July 23, 2007.
195. Rinehart K.L., Holt T.G., Fregeau N.L., Stroh J.G., Keifer P.A., Sun F., Li L.H., Martin D.G. Ecteinascidins 729, 743, 745, 759A, 759B, and 770: Potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinate. J. Org. Chem. 1990, 55:4512-4515.
196. Wright A.E., Forleo D.A., Gunawardana G.P., Gunasekera S.P., Koehn F.E., McConnell O.J. Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinate. J. Org. Chem. 1990, 55:4508-4512.
197. Cuevas C., Perez M., Martin M., Chicharro J.L., Fernandez-Rivas C., Flores M., Francesch A., Gallefo P., Zarzuelo M., de la Calle F., Garcia J., Polanco C., Rodriguez I., Manzanares I. Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B. Org. Lett. 2000, 2:2545-2548.
198. Hirata Y., Uemura D. Halichondrins - antitumor polyether macrolides from a marine sponge. Pure Appl. Chem. 1986, 58:701-710.
199. Pettit G.R., Herald C.L., Boyd M.R., Leet J.E., Dufresne C., Doubek D.L., Schmidt J.M., Cerny R.L., Hooper J.N.A., Rutzler K.C. Antineoplastic agents. 219. Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. J. Med. Chem. 1991, 34:3339-3340.
200. Choi H.-W., Demeke D., Kang F.-A., Kishi Y., Nakajima K., Nowak P., Wan Z.-K., Xie C. Synthetic studies on the marine natural product halichondrins. Pure Appl. Chem. 2003, 75:1-17.
201. Zheng W., Seletsky B.M., Palme M.H., Lydon P.J., Singer L.A., Chase C.E., Lemelin C.A., Shen Y., Davis H., Tremblay L., Towle M.J., Salvato K.A., Wels B.F., Aalfs K.K., Kishi Y., Littlefield B.A., Yu M.J. Macrocyclic ketone analogues of halichondrin B. Bioorg. Med. Chem. Lett. 2004, 14:5551-5554.
202. Pettit G.R., Herald C.L., Doubek D.L., Herald D.L., Arnold E., Clardy J. Isolation and structure of bryostatin 1. J. Am. Chem. Soc. 1982, 104:6846-6848.
203. Newman D.J. Bryostatin - from bryozoan to cancer drug. Bryozoans in Space and Time 1996, 9-17. NIWA, Wellington, NZ. D.P. Gordon, A.M. Smith, J.A. Grant-Mackie (Eds.).
204. Newman D.J. The bryostatins. Anticancer Agents from Natural Products 2005, CRC Press, Boca Raton, FL. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
205. Wongsrichanalai C., Pickard A.L., Wernsdorfer W.H., Meshnick S.R. Epidemiology of drug-resistant malaria. Lancet Infect. Diseases 2002, 2:209-218.
206. Klayman D.L. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985, 228:1049-1055.
207. O'Neill P.M., Posner G.H. A medicinal chemistry perspective on artemisinin and related endoperoxides. J. Med. Chem. 2004, 47:2945-2964.
208. Vennerstrom J.L., Arbe-Barnes S., Brun R., Charman S.A., Chiu F.C.K., Chollet J., Dong Y., Dorn A., Hunziker D., Matile H., McIntosh K., Padmanilayam M., Santo Tomas J., Scheurer C., Scorneaux B., Tang Y., Urwyler H., Sergio W., Charman W.N. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 2004, 430:900-904.
209. Posner G.H., Paik I.-H., Chang W., Borstnik K., Sinishtaq S., Rosenthal A.S., Shapiro T.A. Malaria-infected mice are cured by a single dose of novel artemisinin derivatives. J. Med. Chem. 2007, 50:2516-2519.
210. Cragg G.M., Newman D.J. Plants as a source of anti-cancer and anti-HIV agents. Ann. Appl. Biol. 2003, 143:127-133.
211. Koehn F.E., Carter G.T. The evolving role of natural products in drug discovery. Nat. Drug Discov. Rev. 2005, 4:206-220.
212. Maison W. Natural products research: Renaissance with strengthened integration of biology and chemistry. Angew. Chem. Int. Ed. 2005, 45:3000-3002.
213. Newman D.J., Cragg G.M. Advanced preclinical and clinical trials of natural products and related compounds from marine sources. Curr. Med. Chem. 2004, 11:1693-1713.
214. Newman D.J., Cragg G.M., Holbeck S., Sausville E.A. Natural products and derivatives as leads to cell cycle pathway targets in cancer chemotherapy. Curr. Cancer Drug Targ. 2002, 2:279-308.
215. Paterson I., Anderson A.E. The renaissance of natural products as drug candidates. Science 2005, 310:451-453.
216. Waldmann H. At the crossroads of chemistry and biology. Bioorg. Med. Chem. 2003, 11:3045-3051.
217. Stahl P., Kissau L., Mazitschek R., Giannis A., Waldmann H. Natural Product derived receptor tyrosine kinase inhibitors: identification of IGF1R, tie-2, and VEGFR-3 inhibitors. Angew. Chem. Int. Ed. 2002, 41:1174-1178.
218. Thutewohl M., Kissau L., Popkirova B., Karaguni I.-M., Nowak T., Bate M., Kuhlmann J., Müller O., Waldmann H. Solid-phase synthesis and biological evaluation of a pepticinnamin E library. Angew. Chem. Int. Ed. 2002, 41:3616-3620.
219. Nicolaou K.C., Hughes R., Cho S.Y., Winssinger N., Labischinski H., Endermann R. Synthesis and biological evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria: target-accelerated combinatorial synthesis. Chem. Eur. J. 2001, 7:3824-3843.
220. Lessman T., Leuenberger M.G., Menninger S., Lopez-Canet M., Muller O., Hummer S., Bormann J., Korn K., Fava E., Zerial M., Mayer T.U., Waldmann H. Natural product-derived modulators of cell cycle progression and viral entry by enantioselective oxa diels-alder reactions on the solid phase. Chem. Biol. 2007, 14:443-451.
221. Wipf P., Reeves J.T., Balachandran R., Giuliano K.A., Hamel E., Day B.W. Synthesis and biological evaluation of a focused mixture library of analogues of the antimitotic marine natural product curacin A. J. Am. Chem. Soc. 2000, 122:9391-9395.
222. Crowley B.M., Boger D.L. Total synthesis and evaluation of [psi[CH2NH]Tpg4]vancomycin aglycon: Reengineering vancomycin for Dual D-Ala-D-Ala and D-Ala-D-Lac binding. J. Am. Chem. Soc. 2006, 128:2885-2892.
223. Sudek S., Lopanik N.B., Waggoner L.E., Hildebrand M., Anderson C., Liu H., Patel A., Sherman D.H., Haygood M.G. Identification of the putative bryostatin polyketide synthase gene cluster from "Candidatus Endobugula sertula", the uncultivated microbial symbiont of the marine bryozoan Bugula neritina. J. Nat. Prod. 2007, 70:67-74.
224. Jayasuriya H., Herath K.B., Zhang C., Zink D.L., Basilio A., Genilloud O., Diez M.T., Vicente F., Gonzalez I., Salazar O., Pelaez F., Cummings R., Ha S., Wang J., Singh S.B. Isolation and structure of platencin: a FabH and FabF dual inhibitor with potent broad-spectrum antibiotic activity. Angew. Chem. Int. Ed. 2007, 4684-4688.
225. Young K., Jayasuriya H., Ondeyka J.G., Herath K., Zhang C., Kodali S., Galgoci A., Painter R., Brown-Driver V., Yamamoto R., Silver L.L., Zheng Y., Ventura J.I., Sigmund J., Ha S., Basilio A., Vincente F., Tormo J.R., Pelaez F., Youngman P., Cully D., Barett J.F., Schmatz D., Singh S.B., Wang J. Discovery of FabH/FabF inhibitors from natural products. Antimicrob. Ag. Chemother. 2006, 50:519-526.
226. Singh S.B., Zink D.L., Huber J., Genilloud O., Salazar O., Diez M.T., Basilio A., Vincente F., Byrne K.M. Discovery of lucensimycins A and B from Streptomyces lucensis MA7349 using an antisense strategy. Org. Lett. 2006, 8:5449-5452.
227. Nicolaou K.C., Li D., Edmonds D.J. Total synthesis of platensimycin. Angew. Chem. Int. Ed. 2006, 45:7086-7090.
228. Nicolaou K.C., Edmonds D.J., Li A., Tria G.S. Asymmetric total syntheses of platensimycin. Angew. Chem. Int. Ed. 2007, 46:3942-3945.
229. Nicolaou K.C., Lister T., Denton R.M., Montero A., Edmonds D.J. Adamantaplatensimycin: a bioactive analogue of platensimycin. Angew. Chem. Int. Ed. 2007, 46:4712-4714.
230. Zahner H., Drautz H., Weber W. Novel approaches to metabolite screening. Bioactive Microbial Products: Search and Discovery 1982, 51-70. Academic Press, London. J.D. Bu'Lock, L.J. Nisbet, D.J. Winstanley (Eds.).
231. Banskota A.H., Mcalpine J.B., Sørensen D., Ibrahim A., Aouidate M., Piraee M., Alarco A.M., Farnet C.M., Zazopoulos E. Genomic analyses lead to novel secondary metabolites. Part 3. ECO-0501, a novel antibacterial of a new class. J. Antibiot. 2006, 59:533-542.
232. Clardy J., Fischbach M.A., Walsh C.T. New antibiotics from bacterial natural products. Nat. Biotech. 2006, 24:1541-1550.
233. Rondon M.R., Raffel S.J., Goodman R.M., Handelsman J. Toward functional genomics in bacteria: Analysis of gene expression in Escherichia coli from a bacterial artificial chromosome library of Bacillus cereus. Proc. Natl. Acad. Sci. USA 1999, 96:6451-6455.
234. Bode H.B., Muller R. The impact of bacterial genomics on natural product research. Angew. Chem. Int. Ed. 2005, 44:6828-6846.
235. Rachid S., Gerth K., Kochems I., Muller R. Deciphering regulatory mechanisms for secondary metabolite production in the myxobacterium Sorangium cellulosum So ce56. Mol. Microbiol. 2007, 63:1783-1796.